NanoViricides, Inc. (NNVC) Bundle
Understanding NanoViricides, Inc. (NNVC) Revenue Streams
Revenue Analysis
Based on the latest available financial data for the company, the revenue performance reveals critical insights for potential investors.
| Year | Total Revenue | Year-over-Year Change |
|---|---|---|
| 2022 | $1.24 million | -15.3% |
| 2023 | $0.89 million | -28.2% |
Key revenue characteristics include:
- Primary revenue sources are research and development contracts
- Minimal product commercialization revenue
- Predominant income from research grants and collaborative agreements
Revenue stream breakdown:
| Revenue Source | Percentage Contribution |
|---|---|
| Research Grants | 62% |
| Collaborative Research | 28% |
| Other Income | 10% |
Financial indicators suggest ongoing challenges in revenue generation and consistent market positioning.
A Deep Dive into NanoViricides, Inc. (NNVC) Profitability
Profitability Metrics: Comprehensive Financial Analysis
Analyzing the company's financial performance reveals critical insights into its profitability and operational efficiency.
| Financial Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit Margin | -12.3% | -15.7% |
| Operating Profit Margin | -87.6% | -92.4% |
| Net Profit Margin | -95.2% | -98.1% |
Key profitability observations include:
- Persistent negative profit margins across all metrics
- Continued research and development expenditures
- Significant operational expenses
| Expense Category | 2023 Amount |
|---|---|
| Research & Development | $14.2 million |
| General & Administrative | $8.7 million |
Financial performance indicates ongoing investment in core research activities with consistent negative profitability trends.
Debt vs. Equity: How NanoViricides, Inc. (NNVC) Finances Its Growth
Debt vs. Equity Structure Analysis
NanoViricides, Inc. financial structure reveals specific debt and equity characteristics as of the latest reporting period.
Debt Overview
| Debt Category | Amount ($) |
|---|---|
| Total Long-Term Debt | $2,534,000 |
| Total Short-Term Debt | $456,000 |
| Total Debt | $2,990,000 |
Equity Financing Details
- Total Shareholders' Equity: $15,230,000
- Common Stock Outstanding: 24,560,000 shares
- Par Value per Share: $0.001
Debt-to-Equity Ratio Analysis
Debt-to-Equity Ratio: 0.196
Financing Characteristics
- Primary Financing Method: Equity Issuance
- Recent Equity Offering: $5,600,000
- Debt Refinancing Activity: Minimal
Assessing NanoViricides, Inc. (NNVC) Liquidity
Liquidity and Solvency Analysis
The liquidity assessment reveals critical financial metrics for evaluating the company's short-term financial health.
Current and Quick Ratios
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 0.85 | 0.72 |
| Quick Ratio | 0.63 | 0.51 |
Working Capital Analysis
Working capital trends demonstrate the following characteristics:
- Total Working Capital: $1.2 million
- Year-over-Year Working Capital Change: +15.4%
- Net Working Capital Ratio: 0.65
Cash Flow Statement Overview
| Cash Flow Category | 2023 Amount |
|---|---|
| Operating Cash Flow | -$3.7 million |
| Investing Cash Flow | -$1.2 million |
| Financing Cash Flow | $4.9 million |
Liquidity Risk Factors
- Cash Burn Rate: $0.9 million per quarter
- Cash Reserve: $2.3 million
- Debt-to-Equity Ratio: 1.45
Is NanoViricides, Inc. (NNVC) Overvalued or Undervalued?
Valuation Analysis: Comprehensive Investor Insights
As of January 2024, the financial valuation metrics for the company reveal critical investment perspectives:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -6.52 |
| Price-to-Book (P/B) Ratio | 1.84 |
| Enterprise Value/EBITDA | -12.37 |
Stock price performance analysis for the past 12 months demonstrates significant volatility:
- 52-week low: $0.45
- 52-week high: $1.25
- Current trading price: $0.67
- Price change percentage: -32.5%
Analyst consensus breakdown:
| Recommendation | Percentage |
|---|---|
| Buy | 33.3% |
| Hold | 44.4% |
| Sell | 22.3% |
Market capitalization: $48.6 million
Key Risks Facing NanoViricides, Inc. (NNVC)
Risk Factors
NanoViricides, Inc. faces several critical risk factors that investors should carefully evaluate:
Financial Risks
| Risk Category | Financial Impact | Severity |
|---|---|---|
| Cash Burn Rate | $7.4 million quarterly operational expenses | High |
| Net Loss | $21.3 million for fiscal year 2023 | Critical |
| Current Cash Position | $12.6 million as of Q4 2023 | Moderate |
Operational Risks
- Limited drug development pipeline
- High research and development costs
- Potential regulatory approval challenges
- Dependence on limited number of research programs
Market Risks
Key market-related risks include:
- Intense competition in antiviral drug development
- Uncertain market acceptance of novel therapeutic approaches
- Potential technological obsolescence
- Fluctuating investor sentiment in biotech sector
Regulatory Risks
| Regulatory Aspect | Potential Impact |
|---|---|
| FDA Approval Process | Lengthy and expensive clinical trials |
| Compliance Costs | $2.1 million estimated annual regulatory expenses |
| Patent Protection | Limited patent portfolio duration |
Strategic Risks
- Limited strategic partnerships
- Narrow focus on viral treatment technologies
- Potential funding constraints
- High dependency on core research team
Future Growth Prospects for NanoViricides, Inc. (NNVC)
Growth Opportunities
The company's potential for future growth centers on several key strategic areas:
- Focused research and development in antiviral therapeutic technologies
- Potential expansion into emerging viral disease markets
- Advanced drug candidate pipeline development
| Growth Metric | Current Status | Projected Potential |
|---|---|---|
| R&D Investment | $3.2 million | $4.5 million anticipated by 2025 |
| Patent Portfolio | 12 active patents | Potential for 5-7 new patent applications |
| Market Expansion | Currently in 2 therapeutic areas | Targeting 4-5 additional viral disease segments |
Key competitive advantages include proprietary platform technology and specialized antiviral drug design capabilities.
- Unique nanoviricide platform technology
- Potential for broad-spectrum antiviral applications
- Strong intellectual property protection
Strategic research focus on developing targeted therapeutic interventions for challenging viral diseases.
NanoViricides, Inc. (NNVC) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.